Preclinical Validation of New Anti-melanoma Compounds (NCT03798977) | Clinical Trial Compass
CompletedNot Applicable
Preclinical Validation of New Anti-melanoma Compounds
France20 participantsStarted 2018-02-01
Plain-language summary
This research program is in keeping with the chemistry/biology/clinical interface and gathers 4 teams with complementary expertise in these respective fields. It will allow deciphering the mechanism(s) of action of new Thiazole-Benzenesulfonamide family (TZB) derivatives on metastatic melanoma sensitive and resistant to BRAF and MEK inhibitors. Investigators will use melanoma cell lines and primary cells from patients to validate these compounds in collaboration with clinical team 2 and 4. In conclusion, the investigators expect to establish the proof of concept that this new class of bioactive molecules (first in class) we developed in collaboration with Team 3 have the potential to go to the clinic for the treatment of highly aggressive cancers and particularly metastatic melanoma sensitive and resistant B-Raf and MEK inhibitors. Furthermore, the realization of this project can undoubtedly increase the knowledge of mechanisms and signaling pathways that are involved in resistant to BRAF and MEK inhibitors, and allow the selection of drug candidates capable of restoring the sensitivity of these melanoma cells.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient with metastatic melanoma
* Not opposition of the patient will have been looked for
Exclusion Criteria:
* Primary resistance,
* Absence of resistance,
* Patient already included in other trials
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial was focused on preclinical validation — meaning it was studied in a lab setting rather than in human patients — can you help me understand what stage this research is at and whether any human trials based on these findings are planned or already underway?
2This trial was specifically looking at compounds targeting BRAF mutations in melanoma — do I have a BRAF mutation, and if so, how does that affect which treatments might be most relevant for me?
3Because this study is completed but was preclinical, does that mean the compounds tested here aren't yet available as treatment options, and what approved BRAF-targeted therapies might already be an option for my situation?
4Are there any active or upcoming human clinical trials building on this kind of anti-melanoma compound research that you think would be worth considering given my specific diagnosis?
5Given that this was a foundational research study rather than a treatment trial, should we focus first on established standard-of-care options, and how would you weigh those against waiting for newer compounds that are still in early development?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.